Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 30, Issue 3-4, 2008, Pages 267-276

  Hirooka, Yoshitaka ^a   Kimura, Yoshikuni ^a   Sagara, Yoji ^a   Ito, Koji ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin receptors; Blood pressure; Calcium channel blockers; Endothelium

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTANE; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLYCERYL TRINITRATE; NORADRENALIN; REACTIVE OXYGEN METABOLITE; RENIN; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; JAPANESE; LONG TERM CARE; MALE; OXIDATIVE STRESS; URINARY EXCRETION; VASODILATATION;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; DEOXYGUANOSINE; DINOPROST; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; REGIONAL BLOOD FLOW; TETRAZOLES; VALINE; VASODILATION;

EID: 42349105620     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802071000     Document Type: Article

References (28)

1. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork, A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet. 2004;363:2022-2031.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
3. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther. 2004;311:989-995.
4. Hirooka Y, Kimura Y, Nozoe M, Sagara Y, Ito K, Sunagawa K. Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2006;29:49-56.
5. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial function in hypertensive patients. Circulation. 2001;104:191-196.
6. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Lüscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ. Endothelial function and dysfunction, part II: Association with cardiovascular risk factors and diseases. A statement by the working group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertens. 2005;23:233-246.
7. Panza J, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
8. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229.
9. Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension. 1992;20:175-180.
10. Taddei S, Virdis A, Ghiadoni L, Matti P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens. 1998;16:447-456.
11. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, Salvetti A. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943-948.
12. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension. 2000;35:501-506.
13. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol. 2002;39:257-265.
14. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function dysfunction, part I: Methodological issues for assessment in the different vascular beds: A statement by the working group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertens. 2005;23:7-17.
15. Hozawa A, Ebihara S, Ohmori K, Kuriyama S, Ugajin T, Koizumi Y, Suzuki Y, Matsui T, Arai H, Tsubono Y, Sasaki H, Tsuji I. Increased plasma 8-isoprostane levels in hypertensive subjects: The Tsurugaya Project. Hypertens Res. 2004;27:557-561.
16. 2α as a risk marker in patients with coronary heart disease: A matched case-control study. Circulation. 2004;109: 843-848.
17. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N, Ishida T, Ishida M, Yoshizumi M, Kambe M. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res. 2005;28:889-894.
18. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
19. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
20. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin M-S, Ahn TH, Choi IS, Shin EK. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905-910.
21. Koh KK, Han SH, Chung W-J, Ahn JY, Jin DK, Kim HS, Park GS, Kang WC, Ahn TH, Shin EK. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol. 2004;93:1432-1435.
22. On Y-K, Kim C-H, Oh B-H, Lee M-M, Park Y-B. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res. 2002;25:365-371.
23. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, Brun C, Agabiti-Rosei E. Effect of treatment of flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension. 1999;33:575-580.
24. Ghiadoni L, Magagna A, Versari D, Kardasz I, Hunag Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281-1286.
25. Ghiadoni L, Huang Y, Magagna A, Buralli S, Taddei S, Salvetti A. Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens. 2001;19:547-551.
26. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study. J Am Coll Cardiol. 2000;35:284-291.
27. Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T, Hata T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997;29:286-290.
28. Hirooka Y, Eshima K, Setoguchi S, Kishi T, Egashira K, Takeshita A. Vitamin C improves attenuated angiotensin II-induced endothelium-dependent vasodilation in human forearm vessels. Hypertens Res. 2003;26:953-959.